PriceTargets.com logo

Zymeworks - ZYME Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $33.00
  • Forecasted Upside: 46.47%
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 4 Strong Buy Ratings
$22.53 As of 01/30/2026 05:00 PM ET
▲ +0.15 (0.67%)

This chart shows the closing price for ZYME by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Zymeworks Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZYME and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZYME

Analyst Price Target is $33.00
▲ +46.47% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Zymeworks in the last 3 months. The average price target is $33.00, with a high forecast of $33.00 and a low forecast of $33.00. The average price target represents a 46.47% upside from the last price of $22.53.

This chart shows the closing price for ZYME for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 contributing investment analysts is to buy stock in Zymeworks. This rating has held steady since December 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/5/2025
  • 3 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/3/2025
  • 4 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
1/2/2026
  • 4 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/1/2026

Latest Recommendations

  • 4 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/17/2025Truist FinancialUpgradeStrong-Buy
12/12/2025Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$33.00
12/3/2025Citizens JmpUpgradeStrong-Buy
11/26/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
10/28/2025Zacks ResearchUpgradeHold ➝ Strong-Buy
10/24/2025Wells Fargo & CompanyUpgradeHold
10/14/2025HC WainwrightUpgradeHold ➝ Strong-Buy
10/9/2025B. RileyUpgradeStrong-Buy
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
(Data available from 2/2/2021 forward)

News Sentiment Rating

0.57 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
9/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 6 very positive mentions
  • 24 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 5 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025
  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2026
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2026

Current Sentiment

  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Zymeworks logo
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Read More

Today's Range

Now: $22.53
Low: $22.00
High: $22.77

50 Day Range

MA: $25.22
Low: $22.31
High: $27.62

52 Week Range

Now: $22.53
Low: $9.03
High: $28.49

Volume

560,163 shs

Average Volume

941,426 shs

Market Capitalization

$1.69 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Zymeworks?

The following Wall Street sell-side analysts have issued stock ratings on Zymeworks in the last twelve months: B. Riley, Citizens Jmp, HC Wainwright, Truist Financial Corporation, Wall Street Zen, Weiss Ratings, Wells Fargo & Company, and Zacks Research.
View the latest analyst ratings for ZYME.

What is the current price target for Zymeworks?

0 Wall Street analysts have set twelve-month price targets for Zymeworks in the last year. Their average twelve-month price target is $33.00, suggesting a possible upside of 46.5%. Wells Fargo & Company has the highest price target set, predicting ZYME will reach $33.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $33.00 for Zymeworks in the next year.
View the latest price targets for ZYME.

What is the current consensus analyst rating for Zymeworks?

Zymeworks currently has 1 sell rating, 1 hold rating, 1 buy rating and 4 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZYME will outperform the market and that investors should add to their positions of Zymeworks.
View the latest ratings for ZYME.

What other companies compete with Zymeworks?

Other companies that are similar to Zymeworks include Grifols, Belite Bio, PTC Therapeutics, ImmunityBio and Cogent Biosciences. Learn More about companies similar to Zymeworks.

How do I contact Zymeworks' investor relations team?

Zymeworks' physical mailing address is 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709. The company's listed phone number is (302) 274-8744 and its investor relations email address is [email protected]. The official website for Zymeworks is zymeworks.com. Learn More about contacing Zymeworks investor relations.